iBio, Inc. Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2024, iBio’s fiscal third quarter. The request metadata identifies “2023 Q3,” but the filing is for fiscal 2024 Q3. Amounts are in thousands unless otherwise stated.
Business context
iBio is a preclinical biotechnology company developing AI-enabled precision antibodies. Its platform includes epitope-steering, StableHu antibody optimization, EngageTx T-cell engagers and ShieldTx antibody masking. The company has discontinued its CDMO operations and is seeking to sell the Bryan, Texas facility and related assets.
The company’s pipeline remains preclinical, focused primarily on oncology, obesity and cardiometabolic diseases. Management expects limited revenue from pipeline development and does not anticipate significant revenue from the AI discovery platform for several years.
Financial performance and position
| Metric | Three months ended March 31 | Change | Nine months ended March 31 | Change |
|---|---|---|---|---|
| Revenue | $0 in 2024; $0 in 2023 | — | $50 in 2024; $0 in 2023 | Up $50 |
| R&D expense | $904; $2,644 | Down $1,740 | $4,045; $7,971 | Down $3,926 |
| G&A expense | $2,722; $3,525 | Down $803 | $9,230; $16,407 | Down $7,177 |
| Total operating expenses | $3,626; $6,169 | Down $2,543 | $13,275; $24,378 | Down $11,103 |
| Net loss from continuing operations | $2,635; $6,279 | Improved $3,644 | $12,197; $24,379 | Improved $12,182 |
| Total net loss | $3,172; $7,294 | Improved $4,122 | $17,129; $58,977 | Improved $41,848 |
| Loss per share | $0.85; $11.07 | Improved $10.22 | $7.62; $111.28 | Improved $103.66 |
Revenue and gross margins are not meaningful because the company generated no quarterly revenue and only $50 of revenue year-to-date. The nine-month revenue was a nonrefundable upfront license fee. The company remains loss-making and has an accumulated deficit of $306.1 million as of March 31, 2024.
- Other income: The quarter included a $1.0 million gain from the sale of PD-1 intellectual property to Otsuka. The transaction also provides potential milestone payments of up to $52.5 million, which have not been recognized.
- Discontinued operations: The CDMO business generated a loss of $537 for the quarter and $4,932 year-to-date, including a $3.1 million fixed-asset impairment charge in the second quarter.
- Operating cash flow: Net cash used in operating activities was $13.7 million for the nine months, compared with $25.5 million in the prior-year period.
- Investing cash flow: Net cash provided was $1.1 million, primarily from the $1.0 million PD-1 asset sale.
- Financing cash flow: Net cash provided was $11.5 million, primarily from equity issuance and warrant exercises, partially offset by debt repayments.
- Liquidity: Cash, cash equivalents and restricted cash totaled $6.4 million at March 31, 2024, including $1.1 million of restricted cash. Cash and cash equivalents alone were $5.3 million.
- Balance sheet: Total assets were $50.2 million and total liabilities were $25.3 million. Stockholders’ equity was $24.9 million.
Debt and capital structure
- The Woodforest Term Loan had a balance of approximately $12.7 million at March 31, 2024 and was amended to mature May 15, 2024. It is secured by the Bryan facility and other CDMO collateral, and iBio has guaranteed the obligations.
- The company had approximately $1.0 million outstanding under a January 2024 term promissory note with Loeb Term Solutions, secured by substantially all company assets other than certain patent-related intellectual property.
- Equipment financing totaled $283, and insurance premium financing totaled approximately $340 at March 31, 2024.
- Common shares outstanding increased from 1.0 million at June 30, 2023 to 8.5 million at March 31, 2024, reflecting equity financings, warrant exercises and the effects of the November 2023 reverse stock split.
- The company had 10.7 million potential shares from warrants excluded from diluted loss per share because they were antidilutive.
Material changes versus the prior comparable period
- Quarterly operating expenses declined 41%, primarily due to lower personnel costs, reduced external consulting and in-house performance of certain research activities.
- Nine-month operating expenses declined 46%, reflecting workforce reductions, lower consulting and supply costs, and the absence of certain prior-year impairment charges.
- The nine-month net loss declined substantially because the prior-year period included $17.6 million of CDMO fixed-asset impairments, $4.9 million of inventory write-downs and other wind-down costs.
- iBio completed the sale of its PD-1 assets to Otsuka for $1.0 million in February 2024.
- In March 2024, iBio entered into a private placement for gross proceeds of approximately $15.1 million, consisting of common stock, pre-funded warrants and Series E warrants. The placement closed April 1, 2024, generating net proceeds of approximately $14.1 million.
- During the quarter, exercises of pre-funded and Series C and D warrants generated $4.3 million. An additional $192 was received from warrant exercises in April 2024.
- iBio entered into an AstralBio collaboration covering four cardiometabolic targets and an option to license three additional targets.
Guidance, outlook, risks and unusual items
- Going concern: Management states that recurring losses, negative operating cash flow, limited cash resources and the Woodforest Term Loan maturity create substantial doubt about the company’s ability to continue as a going concern for at least 12 months after filing.
- Post-quarter liquidity: As of the filing date, cash, cash equivalents and restricted cash were approximately $17.9 million, including the private-placement proceeds. Management stated this amount was not expected to fund operations beyond the first quarter of fiscal 2025 unless the facility is sold, the term loan is restructured, spending is reduced or additional capital is raised.
- Facility sale risk: A previously announced facility sale agreement was terminated by the buyer in November 2023. The facility remains for sale, but the filing states that there was no buyer at a price sufficient to repay the Term Loan in full.
- Default and foreclosure risk: Failure to repay, extend or restructure the Woodforest loan could result in acceleration, enforcement against collateral, a deficiency claim and material disruption to operations.
- Funding dependence: iBio expects continuing operating losses and approximately $1.5 million of monthly negative operating cash flow. Additional equity, debt, licensing, collaboration or asset-sale proceeds may be required.
- Development risk: IBIO-101 remains preclinical. Management intends to seek an IND filing in calendar 2025, subject to favorable competitor data and funding availability. No product candidate has been commercialized.
- Asset impairment risk: The $5.0 million IBIO-101 indefinite-lived intangible asset had an estimated fair value of $5.9 million at March 31, 2024, but management identified the asset as at risk of future impairment.
- Dilution: The Series E warrants cover up to 5.3 million shares at an exercise price of $2.64 per share. Exercise of these and other outstanding warrants could materially dilute existing holders.
- Subsequent events: The company adopted an officer severance plan, made substantial option grants in April and May 2024, and appointed CEO and CSO Martin Brenner to the board effective June 1, 2024 following a director resignation.
Investor verification priorities
- Verify whether the Woodforest Term Loan was repaid, extended, restructured or became subject to default after its May 15, 2024 maturity date.
- Confirm the status, expected proceeds and closing timetable for any sale or other disposition of the Bryan facility.
- Reconcile the post-filing cash balance and monthly cash burn with the company’s stated runway through the first quarter of fiscal 2025.
- Review the full dilution impact of the private placement, pre-funded warrants, Series E warrants and other outstanding warrants.
- Assess whether iBio can secure additional financing or partnerships without materially unfavorable terms.
- Track IBIO-101’s IND-enabling progress and whether the stated 2025 IND objective remains achievable.
- Evaluate the carrying value of the IBIO-101 intangible asset and the potential for additional facility or intellectual-property impairments.